Neuralink implanted chips in two patients for the first time today.

Elon Musk's neurotechnology startup Neuralink has just announced that it has successfully performed two brain chip implants in a single day for the first time.

This event is considered a significant milestone in the development and commercialization of Neuralink's brain-computer interface technology, opening up prospects for widespread application in the treatment of serious neurological diseases.

This information was published on the website of Teslarati, a multi-platform media company based in California (USA), which provides news, analysis, and content related to companies founded by billionaire Elon Musk, such as Tesla, SpaceX, and related technologies.

According to updated information released on the morning of July 21st, US time, two patients, identified as patients number 8 and 9, had a chip called "Link" implanted in their brains over the weekend. This device, about the size of a coin, is implanted in the brain through minimally invasive surgery.

Although Neuralink did not disclose the exact dates of the surgeries, they confirmed that both procedures took place on the same day. Both patients are currently recovering well and are in good spirits.

According to Neuralink, the company's implant has "ultrafine" fibers that help transmit signals in the brains of patients who receive the device.

Billionaire Elon Musk, who co-founded Neuralink in 2016, emphasized that this technology could bring about “revolutionary changes for millions, even billions of people.”

Neuralink's nerve implant technology is currently being tested on patients with amyotrophic lateral sclerosis (ALS) or cervical spinal cord injuries, conditions that can severely impair a patient's mobility and communication abilities.

In the long term, Neuralink aims to expand its treatment scope to include more common neurological disorders such as anxiety, depression, or even cases of vision loss.

In May 2023, the U.S. Food and Drug Administration (FDA) authorized Neuralink to test the implantation of chips in the human brain. Then, in September, Neuralink was authorized to recruit polio patients for a six-year human brain implant trial.

Several companies are currently conducting similar research, including Sychron, which is based in Australia.

In July 2022, Sychron announced that it had implanted a brain-computer interface device into a patient with ALS in the United States. The purpose of this implant is to allow the patient to communicate, even after losing motor skills, by using thought to send emails and text messages.

(VNA/Vietnam+)

Source: https://www.vietnamplus.vn/neuralink-lan-dau-cay-chip-cho-2-benh-nhan-trong-ngay-post1051120.vnp